Interstitial cystitis
Conditions
Interventions
2.5mg of tadarafil is administered once a day for 12 weeks.
Sponsors
Fujita Health University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed as interstitial cystitis 2.Patients who are considered eligible for the study by the attending physician 3.Patients who can understand the contents of the questionnaire without the help of others, and who can answer on their own 4.Patients who voluntarily provide written consent to participate in the study
Exclusion criteria
Exclusion criteria: 1.Patients with a history of hypersensitivity to components of this drug 2.Patients with a history of serious cardiovascular (It have been reported the risk og tachycardia) 3.Patients with severe hypertension 4.Patients with severe liver dysfunction (Child-Pugh score 10 or more) [There is a possibility that the blood concentration is excessively increased.] 5.Patients treated with flecainide acetate or propafenone hydrochloride in administration 6.Patients with chronic bacterial prostatitis or activity of urinary tract infection 7.Patients who carried the radiation therapy to the pelvis 8.Patients who suspected of having prostate cancer by PSA or rectal examination 9.Patients with urethral stricture 10.Patients who are considered ineligible for the study by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The symptoms improved rate after 12 weeks administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of cystoscopy findings,urinary frequency,voided volume after 12 weeks administration | — |
Countries
Japan
Contacts
Public ContactHitomi Sasaki
Fujita Health University Medicine/Department of Urology
Outcome results
None listed